Internet Archive Scholar

Early Dexamethasone Use as A Protective Measure In Non-Mechanically Ventilated Critically Ill Patients With COVID-19: A Multicenter, Cohort Study [post]

Khalid Al Sulaiman, Ghazwa B. Korayem, Khalid Eljaaly, Ali F. Altebainawi, Omar Al Harbi, Hisham A. Badreldin, Abdullah Al Harthi, Ghada Al Yousif, Ramesh Vishwakarma, Shorouq Albelwi, Rahaf Almutairi, Maha Almousa (+11 others)
2021 unpublished

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (651.7 kB)
https://web.archive.org/web/20211128005258/https://assets.researchsquare.com/files/rs-1025164/v1/6221f23f-9946-4b90-a0ed-9a90521a5f83.pdf?c=1636732316

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL. The file type is application/pdf.

Background: Dexamethasone showed mortality benefits in COVID-19 patients. However, the optimal timing for dexamethasone initiation to prevent COVID-19 consequences such as respiratory failure requiring MV is debatable. As a result, the purpose of this study is to assess the impact of early dexamethasone initiation in non-MV critically ill patients with COVID19.Methods: A multicenter cohort study including adult patients with COVID-19 admitted to intensive care units (ICUs) and received systemic
more » ... dexamethasone between March 2020 and March 2021. Patients were categorized into two groups based on the timing for dexamethasone initiation (early vs. late). The primary endpoint is developing respiratory failure that required MV; other outcomes were considered secondary. Propensity score matching was used based on the patient's SOFA score, mechanical ventilation (MV) status, prone status, and early use of tocilizumab within 24 hours of ICU admission.Results: Among 208 patients matched using propensity score, 104 had received dexamethasone after 24 hours of ICU admission (1:1 ratio). Among the non-mechanically ventilated patients, late use of dexamethasone was associated with higher odds of developing respiratory failure that required MV (OR [95%CI]: 2.75 [1.12, 6.76], P=0.02). Additionally, late use was associated with longer hospital LOS (Est. [95%CI]: 0.55 [0.22, 0.88], P=0.001).The 30-day and in-hospital mortality were higher in the late group; however, were not statistically significant.Conclusion: Early use of dexamethasone within 24 hours of ICU admission in critically ill patients with COVID-19 might be considered a proactive protective measure in non-mechanically ventilated patients.
doi:10.21203/rs.3.rs-1025164/v1 fatcat:wupwr2j27fe4peqnh7nc2wlnnq
Open Access
Citation

Khalid Al Sulaiman, Ghazwa B. Korayem, Khalid Eljaaly, Ali F. Altebainawi, Omar Al Harbi, Hisham A. Badreldin, Abdullah Al Harthi, Ghada Al Yousif, Ramesh Vishwakarma, Shorouq Albelwi, Rahaf Almutairi, Maha Almousa, Razan Alghamdi, Alaa Alhubaishi, Abdulrahman Alissa, Aisha Alharbi, Rahmah Algarni, Sarah Al Homaid, Khawla Kahtani, Nada Akhani, Abdulaleam Al Atassi, Ghassan Al Ghamdi, Ohoud Aljuhani. "Early Dexamethasone Use as A Protective Measure In Non-Mechanically Ventilated Critically Ill Patients With COVID-19: A Multicenter, Cohort Study." (2021)